Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api).
- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api).
- Richard Francis, Teva’s President and CEO said: “I am excited to welcome Ananth back to Teva to lead the Teva api business during this pivotal time for our company, as we continue to progress on our plan for turning Teva api into a standalone business.
- Having led the former Teva api and Biologics Operations organization at Teva from 2014 to 2018, Dr. Ananth has a deep understanding of Teva’s API business.
- Dr. Ananth stated, “I am very excited to return to Teva to lead the API business, and to join my esteemed colleagues and teams at Teva api – old and new.